Wyoming Drug Utilization Review (WY-DUR)

School of Pharmacy | College of Health Sciences

News

The Wyoming Department of Health is conducting a survey concerning the use and barriers to use of 17-alpha hydroxyprogesterone in pregnant women. If you routinely provide prenatal care for your pregnant patients, please participate in this survey.

The Draft 2017 PDL is available for review. Please submit comments before January 1, 2017.

New Drug Review: Possible P & T Committee Decisions (May 2015)

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org.

Public Comment at Meetings

A new policy for public comment at meetings is effective December 2, 2012.

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the May 10, 2017 P & T Committee meeting.

New language will be added to the Suboxone prior authorization form regarding counseling about neonatal abstinence syndrome and use of birth control in women of child bearing age. 86% of pregnancies in women taking narcotics are unintended. Seventeen Wyoming Medicaid babies had a diagnosis of neonatal abstinence or withdrawal at birth in 2016.
The Nuedexta criteria will be updated to require a diagnosis of pseudobulbar affect with an underlying diagnosis of multiple sclerosis or amyotrophic lateral sclerosis, traumatic brain injury, stroke or dementia.
Emflaza will be limited to use in those with a diagnosis of Duchenne’s Muscular Dystrophy.
Nucala and Cinqair will require a diagnosis of eosinophilic asthma as well as a trial and failure of a medium or high potency inhaled corticosteroid in combination with a long-acting beta agonist, per asthma guidelines.

Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY 82071. Comments should be received prior to July 1, 2017.